Allorion Therapeutics Co. Ltd. has patented nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.
Sironax Ltd. has patented receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of ulcerative colitis, Crohn's disease, psoriasis, rheumatoid arthritis, amyotrophic lateral sclerosis, Alzheimer's disease and viral infections.
Microorganisms such as bacteria, sperm and microalgae have evolved to develop robust actuation systems that enable autonomous motion, and these natural cellular systems have recently emerged as attractive carriers for transporting therapeutics to hard-to-reach body locations. According to a recent publication, researchers from University of California, San Diego have developed a novel algae-based motor platform, with the aim of addressing limitations of cargo delivery into the gastrointestinal (GI) tract.
A protein called apoptosis inhibitor 5 (API-5) protects intestinal Paneth cells, which are disrupted in Crohn’s disease, and could lead to a new treatment for the inflammatory bowel disease. Writing in the Oct. 5, 2022, online issue of Nature, Ken Cadwell, a professor of microbiology at New York University Grossman School of Medicine, and colleagues described testing the protein in a mouse model and in gut organoids with good results. Crohn’s disease is one of two key autoimmune diseases that affect the gut, the second of which is ulcerative colitis. Combined, inflammatory bowel diseases affect around 3 million people in the U.S. While there is currently no cure for these conditions, there are monoclonal antibody therapies available.
Endpoint Health Inc. has announced a new precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.
Terns Pharmaceuticals Inc. has patented thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of nonalcoholic steatohepatitis.
After two years of talks, privately held Ventus Therapeutics Inc. and Novo Nordisk A/S have signed an exclusive worldwide license deal to commercialize candidates from Ventus’ portfolio of peripherally restricted NLR pyrin domain-containing 3 (NLRP3) inhibitors. Along with Roche Holding AG’s September 2020 acquisition of Inflazome Ltd. and Novartis AG’s buyout of subsidiary IFM Tre in April 2019, this is another step by big players to get into the NLRP3 space.
Sino Biopharmaceutical Ltd. subsidiary Chia Tai-Tianqing Pharmaceutical Group Co. Ltd. has acquired greater China rights to lanifibranor from Inventiva SA in a deal worth up to $307 million.
Convalife (Shanghai) Health Technology Co. Ltd. has presented new thyroid hormone receptor α (TR-α) and (TR-β) agonists reported to be useful for the treatment of nonalcoholic fatty liver disease, obesity, liver fibrosis, type 2 diabetes and hypercholesterolemia.
RSS
